ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Treatment Intensification in Metastatic HSPC"
Episode Synopsis
Treatment Intensification in Metastatic HSPC
CME Available: https://auau.auanet.org/node/41733
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.
2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.
3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.
CME Available: https://auau.auanet.org/node/41733
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.
2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.
3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.
More episodes of the podcast AUAUniversity
The Latest Breakthroughs in mHSPC
24/09/2025
In God we trust